1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Opioid Induced Constipation (OIC) Drug Revenue
1.4 Market Analysis by Type
1.4.1 Global Opioid Induced Constipation (OIC) Drug Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Lubiprostone
1.4.3 Methyl Naltrexone Bromide
1.4.4 Naldemedine
1.4.5 Alvimopan
1.4.6 Other
1.5 Market by Application
1.5.1 Global Opioid Induced Constipation (OIC) Drug Market Share by Application: 2021-2026
1.5.2 Hospital Pharmacies
1.5.3 Retail Pharmacies
1.5.4 Online Pharmacies
1.6 Study Objectives
1.7 Years Considered
1.8 Overview of Global Opioid Induced Constipation (OIC) Drug Market
1.8.1 Global Opioid Induced Constipation (OIC) Drug Market Status and Outlook (2015-2026)
1.8.2 North America
1.8.3 East Asia
1.8.4 Europe
1.8.5 South Asia
1.8.6 Southeast Asia
1.8.7 Middle East
1.8.8 Africa
1.8.9 Oceania
1.8.10 South America
1.8.11 Rest of the World
2 Market Competition by Manufacturers
2.1 Global Opioid Induced Constipation (OIC) Drug Production Capacity Market Share by Manufacturers (2015-2020)
2.2 Global Opioid Induced Constipation (OIC) Drug Revenue Market Share by Manufacturers (2015-2020)
2.3 Global Opioid Induced Constipation (OIC) Drug Average Price by Manufacturers (2015-2020)
2.4 Manufacturers Opioid Induced Constipation (OIC) Drug Production Sites, Area Served, Product Type
3 Sales by Region
3.1 Global Opioid Induced Constipation (OIC) Drug Sales Volume Market Share by Region (2015-2020)
3.2 Global Opioid Induced Constipation (OIC) Drug Sales Revenue Market Share by Region (2015-2020)
3.3 North America Opioid Induced Constipation (OIC) Drug Sales Volume
3.3.1 North America Opioid Induced Constipation (OIC) Drug Sales Volume Growth Rate (2015-2020)
3.3.2 North America Opioid Induced Constipation (OIC) Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.4 East Asia Opioid Induced Constipation (OIC) Drug Sales Volume
3.4.1 East Asia Opioid Induced Constipation (OIC) Drug Sales Volume Growth Rate (2015-2020)
3.4.2 East Asia Opioid Induced Constipation (OIC) Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.5 Europe Opioid Induced Constipation (OIC) Drug Sales Volume (2015-2020)
3.5.1 Europe Opioid Induced Constipation (OIC) Drug Sales Volume Growth Rate (2015-2020)
3.5.2 Europe Opioid Induced Constipation (OIC) Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.6 South Asia Opioid Induced Constipation (OIC) Drug Sales Volume (2015-2020)
3.6.1 South Asia Opioid Induced Constipation (OIC) Drug Sales Volume Growth Rate (2015-2020)
3.6.2 South Asia Opioid Induced Constipation (OIC) Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.7 Southeast Asia Opioid Induced Constipation (OIC) Drug Sales Volume (2015-2020)
3.7.1 Southeast Asia Opioid Induced Constipation (OIC) Drug Sales Volume Growth Rate (2015-2020)
3.7.2 Southeast Asia Opioid Induced Constipation (OIC) Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.8 Middle East Opioid Induced Constipation (OIC) Drug Sales Volume (2015-2020)
3.8.1 Middle East Opioid Induced Constipation (OIC) Drug Sales Volume Growth Rate (2015-2020)
3.8.2 Middle East Opioid Induced Constipation (OIC) Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.9 Africa Opioid Induced Constipation (OIC) Drug Sales Volume (2015-2020)
3.9.1 Africa Opioid Induced Constipation (OIC) Drug Sales Volume Growth Rate (2015-2020)
3.9.2 Africa Opioid Induced Constipation (OIC) Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.10 Oceania Opioid Induced Constipation (OIC) Drug Sales Volume (2015-2020)
3.10.1 Oceania Opioid Induced Constipation (OIC) Drug Sales Volume Growth Rate (2015-2020)
3.10.2 Oceania Opioid Induced Constipation (OIC) Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.11 South America Opioid Induced Constipation (OIC) Drug Sales Volume (2015-2020)
3.11.1 South America Opioid Induced Constipation (OIC) Drug Sales Volume Growth Rate (2015-2020)
3.11.2 South America Opioid Induced Constipation (OIC) Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.12 Rest of the World Opioid Induced Constipation (OIC) Drug Sales Volume (2015-2020)
3.12.1 Rest of the World Opioid Induced Constipation (OIC) Drug Sales Volume Growth Rate (2015-2020)
3.12.2 Rest of the World Opioid Induced Constipation (OIC) Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
4 North America
4.1 North America Opioid Induced Constipation (OIC) Drug Consumption by Countries
4.2 United States
4.3 Canada
4.4 Mexico
5 East Asia
5.1 East Asia Opioid Induced Constipation (OIC) Drug Consumption by Countries
5.2 China
5.3 Japan
5.4 South Korea
6 Europe
6.1 Europe Opioid Induced Constipation (OIC) Drug Consumption by Countries
6.2 Germany
6.3 United Kingdom
6.4 France
6.5 Italy
6.6 Russia
6.7 Spain
6.8 Netherlands
6.9 Switzerland
6.10 Poland
7 South Asia
7.1 South Asia Opioid Induced Constipation (OIC) Drug Consumption by Countries
7.2 India
7.3 Pakistan
7.4 Bangladesh
8 Southeast Asia
8.1 Southeast Asia Opioid Induced Constipation (OIC) Drug Consumption by Countries
8.2 Indonesia
8.3 Thailand
8.4 Singapore
8.5 Malaysia
8.6 Philippines
8.7 Vietnam
8.8 Myanmar
9 Middle East
9.1 Middle East Opioid Induced Constipation (OIC) Drug Consumption by Countries
9.2 Turkey
9.3 Saudi Arabia
9.4 Iran
9.5 United Arab Emirates
9.6 Israel
9.7 Iraq
9.8 Qatar
9.9 Kuwait
9.10 Oman
10 Africa
10.1 Africa Opioid Induced Constipation (OIC) Drug Consumption by Countries
10.2 Nigeria
10.3 South Africa
10.4 Egypt
10.5 Algeria
10.6 Morocco
11 Oceania
11.1 Oceania Opioid Induced Constipation (OIC) Drug Consumption by Countries
11.2 Australia
11.3 New Zealand
12 South America
12.1 South America Opioid Induced Constipation (OIC) Drug Consumption by Countries
12.2 Brazil
12.3 Argentina
12.4 Columbia
12.5 Chile
12.6 Venezuela
12.7 Peru
12.8 Puerto Rico
12.9 Ecuador
13 Rest of the World
13.1 Rest of the World Opioid Induced Constipation (OIC) Drug Consumption by Countries
13.2 Kazakhstan
14 Sales Volume, Sales Revenue, Sales Price Trend by Type
14.1 Global Opioid Induced Constipation (OIC) Drug Sales Volume Market Share by Type (2015-2020)
14.2 Global Opioid Induced Constipation (OIC) Drug Sales Revenue Market Share by Type (2015-2020)
14.3 Global Opioid Induced Constipation (OIC) Drug Sales Price by Type (2015-2020)
15 Consumption Analysis by Application
15.1 Global Opioid Induced Constipation (OIC) Drug Consumption Volume by Application (2015-2020)
15.2 Global Opioid Induced Constipation (OIC) Drug Consumption Value by Application (2015-2020)
16 Company Profiles and Key Figures in Opioid Induced Constipation (OIC) Drug Business
16.1 Ironwood Pharmaceuticals
16.1.1 Ironwood Pharmaceuticals Company Profile
16.1.2 Ironwood Pharmaceuticals Opioid Induced Constipation (OIC) Drug Product Specification
16.1.3 Ironwood Pharmaceuticals Opioid Induced Constipation (OIC) Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.2 Purdue Pharma
16.2.1 Purdue Pharma Company Profile
16.2.2 Purdue Pharma Opioid Induced Constipation (OIC) Drug Product Specification
16.2.3 Purdue Pharma Opioid Induced Constipation (OIC) Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.3 Progenics Pharmaceuticals
16.3.1 Progenics Pharmaceuticals Company Profile
16.3.2 Progenics Pharmaceuticals Opioid Induced Constipation (OIC) Drug Product Specification
16.3.3 Progenics Pharmaceuticals Opioid Induced Constipation (OIC) Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.4 Daiichi Sankyo Co
16.4.1 Daiichi Sankyo Co Company Profile
16.4.2 Daiichi Sankyo Co Opioid Induced Constipation (OIC) Drug Product Specification
16.4.3 Daiichi Sankyo Co Opioid Induced Constipation (OIC) Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.5 Nektar Therapeutics
16.5.1 Nektar Therapeutics Company Profile
16.5.2 Nektar Therapeutics Opioid Induced Constipation (OIC) Drug Product Specification
16.5.3 Nektar Therapeutics Opioid Induced Constipation (OIC) Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.6 Pfizer
16.6.1 Pfizer Company Profile
16.6.2 Pfizer Opioid Induced Constipation (OIC) Drug Product Specification
16.6.3 Pfizer Opioid Induced Constipation (OIC) Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.7 Mundipharma International Limited
16.7.1 Mundipharma International Limited Company Profile
16.7.2 Mundipharma International Limited Opioid Induced Constipation (OIC) Drug Product Specification
16.7.3 Mundipharma International Limited Opioid Induced Constipation (OIC) Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.8 Allergan
16.8.1 Allergan Company Profile
16.8.2 Allergan Opioid Induced Constipation (OIC) Drug Product Specification
16.8.3 Allergan Opioid Induced Constipation (OIC) Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.9 Shionogi &
16.9.1 Shionogi & Company Profile
16.9.2 Shionogi & Opioid Induced Constipation (OIC) Drug Product Specification
16.9.3 Shionogi & Opioid Induced Constipation (OIC) Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.10 S.L.A. Pharma
16.10.1 S.L.A. Pharma Company Profile
16.10.2 S.L.A. Pharma Opioid Induced Constipation (OIC) Drug Product Specification
16.10.3 S.L.A. Pharma Opioid Induced Constipation (OIC) Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.11 Cosmo Pharmaceuticals SA
16.11.1 Cosmo Pharmaceuticals SA Company Profile
16.11.2 Cosmo Pharmaceuticals SA Opioid Induced Constipation (OIC) Drug Product Specification
16.11.3 Cosmo Pharmaceuticals SA Opioid Induced Constipation (OIC) Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.12 Sucampo Pharmaceuticals
16.12.1 Sucampo Pharmaceuticals Company Profile
16.12.2 Sucampo Pharmaceuticals Opioid Induced Constipation (OIC) Drug Product Specification
16.12.3 Sucampo Pharmaceuticals Opioid Induced Constipation (OIC) Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.13 Ono Pharmaceutical
16.13.1 Ono Pharmaceutical Company Profile
16.13.2 Ono Pharmaceutical Opioid Induced Constipation (OIC) Drug Product Specification
16.13.3 Ono Pharmaceutical Opioid Induced Constipation (OIC) Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.14 Daewoong Pharmaceutical
16.14.1 Daewoong Pharmaceutical Company Profile
16.14.2 Daewoong Pharmaceutical Opioid Induced Constipation (OIC) Drug Product Specification
16.14.3 Daewoong Pharmaceutical Opioid Induced Constipation (OIC) Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.15 Bausch Health
16.15.1 Bausch Health Company Profile
16.15.2 Bausch Health Opioid Induced Constipation (OIC) Drug Product Specification
16.15.3 Bausch Health Opioid Induced Constipation (OIC) Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.16 Takeda Pharmaceutical Company Limited
16.16.1 Takeda Pharmaceutical Company Limited Company Profile
16.16.2 Takeda Pharmaceutical Company Limited Opioid Induced Constipation (OIC) Drug Product Specification
16.16.3 Takeda Pharmaceutical Company Limited Opioid Induced Constipation (OIC) Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.17 C.B. Fleet Company
16.17.1 C.B. Fleet Company Company Profile
16.17.2 C.B. Fleet Company Opioid Induced Constipation (OIC) Drug Product Specification
16.17.3 C.B. Fleet Company Opioid Induced Constipation (OIC) Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.18 Theravance Biopharma
16.18.1 Theravance Biopharma Company Profile
16.18.2 Theravance Biopharma Opioid Induced Constipation (OIC) Drug Product Specification
16.18.3 Theravance Biopharma Opioid Induced Constipation (OIC) Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
17 Opioid Induced Constipation (OIC) Drug Manufacturing Cost Analysis
17.1 Opioid Induced Constipation (OIC) Drug Key Raw Materials Analysis
17.1.1 Key Raw Materials
17.2 Proportion of Manufacturing Cost Structure
17.3 Manufacturing Process Analysis of Opioid Induced Constipation (OIC) Drug
17.4 Opioid Induced Constipation (OIC) Drug Industrial Chain Analysis
18 Marketing Channel, Distributors and Customers
18.1 Marketing Channel
18.2 Opioid Induced Constipation (OIC) Drug Distributors List
18.3 Opioid Induced Constipation (OIC) Drug Customers
19 Market Dynamics
19.1 Market Trends
19.2 Opportunities and Drivers
19.3 Challenges
19.4 Porter's Five Forces Analysis
20 Production and Supply Forecast
20.1 Global Forecasted Production of Opioid Induced Constipation (OIC) Drug (2021-2026)
20.2 Global Forecasted Revenue of Opioid Induced Constipation (OIC) Drug (2021-2026)
20.3 Global Forecasted Price of Opioid Induced Constipation (OIC) Drug (2015-2026)
20.4 Global Forecasted Production of Opioid Induced Constipation (OIC) Drug by Region (2021-2026)
20.4.1 North America Opioid Induced Constipation (OIC) Drug Production, Revenue Forecast (2021-2026)
20.4.2 East Asia Opioid Induced Constipation (OIC) Drug Production, Revenue Forecast (2021-2026)
20.4.3 Europe Opioid Induced Constipation (OIC) Drug Production, Revenue Forecast (2021-2026)
20.4.4 South Asia Opioid Induced Constipation (OIC) Drug Production, Revenue Forecast (2021-2026)
20.4.5 Southeast Asia Opioid Induced Constipation (OIC) Drug Production, Revenue Forecast (2021-2026)
20.4.6 Middle East Opioid Induced Constipation (OIC) Drug Production, Revenue Forecast (2021-2026)
20.4.7 Africa Opioid Induced Constipation (OIC) Drug Production, Revenue Forecast (2021-2026)
20.4.8 Oceania Opioid Induced Constipation (OIC) Drug Production, Revenue Forecast (2021-2026)
20.4.9 South America Opioid Induced Constipation (OIC) Drug Production, Revenue Forecast (2021-2026)
20.4.10 Rest of the World Opioid Induced Constipation (OIC) Drug Production, Revenue Forecast (2021-2026)
20.5 Forecast by Type and by Application (2021-2026)
20.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2021-2026)
20.5.2 Global Forecasted Consumption of Opioid Induced Constipation (OIC) Drug by Application (2021-2026)
21 Consumption and Demand Forecast
21.1 North America Forecasted Consumption of Opioid Induced Constipation (OIC) Drug by Country
21.2 East Asia Market Forecasted Consumption of Opioid Induced Constipation (OIC) Drug by Country
21.3 Europe Market Forecasted Consumption of Opioid Induced Constipation (OIC) Drug by Countriy
21.4 South Asia Forecasted Consumption of Opioid Induced Constipation (OIC) Drug by Country
21.5 Southeast Asia Forecasted Consumption of Opioid Induced Constipation (OIC) Drug by Country
21.6 Middle East Forecasted Consumption of Opioid Induced Constipation (OIC) Drug by Country
21.7 Africa Forecasted Consumption of Opioid Induced Constipation (OIC) Drug by Country
21.8 Oceania Forecasted Consumption of Opioid Induced Constipation (OIC) Drug by Country
21.9 South America Forecasted Consumption of Opioid Induced Constipation (OIC) Drug by Country
21.10 Rest of the world Forecasted Consumption of Opioid Induced Constipation (OIC) Drug by Country
22 Research Findings and Conclusion
23 Methodology and Data Source
23.1 Methodology/Research Approach
23.1.1 Research Programs/Design
23.1.2 Market Size Estimation
23.1.3 Market Breakdown and Data Triangulation
23.2 Data Source
23.2.1 Secondary Sources
23.2.2 Primary Sources
23.3 Disclaimer